The role of genetic and other biomarkers in NSCLC prognosis

被引：0

作者：

Schveigert, Diana ^{[1
]}

Cicenas, Saulius ^{[1
,2
]}

Bublevic, Jaroslav ^{[2
]}

Askinis, Renatas ^{[1
,2
]}

Sapoka, Virginijus ^{[1
,2
]}

Didziapetriene, Janina ^{[1
,2
]}

机构：

[1] Vilnius Univ, Inst Oncol, Vilnius, Lithuania

[2] Vilnius Univ, Fac Med, Vilnius, Lithuania

来源：

CENTRAL EUROPEAN JOURNAL OF MEDICINE | 2014年 / 9卷 / 03期

关键词：

Non-small cell lung cancer; Biomarkers; Prognosis; CELL LUNG-CANCER; CIRCULATING TUMOR-CELLS; GROWTH-FACTOR RECEPTOR; ERCC1; EXPRESSION; KRAS MUTATION; FREE SURVIVAL; CHEMOTHERAPY; EGFR; DNA; MDM2;

D O I：

10.2478/s11536-013-0290-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The development of non-small-cell lung cancer (NSCLC) is a multistep process, which is triggered and maintained by various factors. Many steps of non-small-cell lung carcinogenesis, risk factors and biomarkers have been identified; however no consistent model has been established of personalized medicine for these patients. Distinct various gene expression, products of mutated genes and other markers such as circulating nucleic acids or tumor cells has been proven to be potential biomarkers of non-small cell lung cancer as well as potential targets for new treatment strategies. This article will highlight promising biomarkers in non-small cell lung cancer prognosis.

引用

页码：382 / 390

页数：9

共 57 条

[1] Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib [J].

Acquaviva, Jaime ;

Smith, Donald L. ;

Sang, Jim ;

Friedland, Julie C. ;

He, Suqin ;

Sequeira, Manuel ;

Zhang, Chaohua ;

Wada, Yumiko ;

Proia, David A. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) :2633-2643

[2]

[Anonymous], J CLIN ONCOL S15

[3]

[Anonymous], PLOS CURR

[4] K-ras mutations in non-small-cell lung carcinoma:: A review [J].

Aviel-Ronen, Sarit ;

Blackhall, Fiona H. ;

Shepherd, Frances A. ;

Tsao, Ming-Sound .

CLINICAL LUNG CANCER, 2006, 8 (01) :30-38

[5]

Bittner N, 2013, PATHOL ONCOL RES, DOI [10.1007/s12253-013-9719-9719, DOI 10.1007/S12253-013-9719-9719]

[6] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].

Brugger, Wolfram ;

Triller, Nadja ;

Blasinska-Morawiec, Maria ;

Curescu, Stefan ;

Sakalauskas, Raimundas ;

Manikhas, Georgy Moiseevich ;

Mazieres, Julien ;

Whittom, Renaud ;

Ward, Carol ;

Mayne, Karen ;

Trunzer, Kerstin ;

Cappuzzo, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120

[7] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

[8] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[9] Immunization with mutant p53- and K-ras-derived peptides in cancer patients:: Immune response and clinical outcome [J].

Carbone, DP ;

Ciernik, IF ;

Kelley, MJ ;

Smith, MC ;

Nadaf, S ;

Kavanaugh, D ;

Maher, VE ;

Stipanov, M ;

Contois, D ;

Johnson, BE ;

Pendleton, CD ;

Seifert, B ;

Carter, C ;

Read, EJ ;

Greenblatt, J ;

Top, LE ;

Kelsey, MI ;

Minna, JD ;

Berzofsky, JA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5099-5107

[10] Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients [J].

Catarino, Raquel ;

Coelho, Ana ;

Araujo, Antonio ;

Gomes, Monica ;

Nogueira, Augusto ;

Lopes, Carlos ;

Medeiros, Rui .

PLOS ONE, 2012, 7 (06)

← 1 2 3 4 5 6 →